Pfizer Inc v. Cipla Ltd

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Pfizer Inc.; FoldRx Pharmaceuticals, LLC; PF Prism Imb BV.; and Wyeth LLC (Delaware & Netherlands)
  • Defendant: Cipla Limited (India)
  • Plaintiff's Counsel: Morris, Nichols, Arsht & Tunnell LLP
• Case Identification: 1:23-cv-00909, D. Del., 08/18/2023
• Venue Allegations: Venue is alleged to be proper because the defendant, Cipla, is a foreign corporation subject to personal jurisdiction in the District of Delaware.
• Core Dispute: Plaintiffs allege that Defendant's submission of an Abbreviated New Drug Application (ANDA) to market a generic version of the drug Vyndamax® constitutes an act of infringement of a patent covering specific crystalline forms of the active ingredient, tafamidis.
• Technical Context: The dispute centers on pharmaceutical formulation technology, where the specific crystalline structure (polymorph) of an active ingredient can affect a drug's stability, manufacturability, and bioavailability.
• Key Procedural History: The lawsuit was initiated under the Hatch-Waxman Act following a notice letter dated July 7, 2023, in which Cipla informed Pfizer of its ANDA filing seeking FDA approval for its generic product. This filing is a statutory act of infringement that allows for patent litigation prior to the commercial launch of the generic drug.

Case Timeline

Date	Event
2014-09-08	U.S. Patent No. 9,770,441 Priority Date
2017-09-26	U.S. Patent No. 9,770,441 Issues
2023-07-07	Cipla sends Notice Letter of ANDA filing
2023-07-26	Plaintiffs' counsel sends letter to Cipla
2023-08-18	Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 9,770,441 - "CRYSTALLINE SOLID FORMS OF 6-CARBOXY-2-(3,5-DICHLOROPHENYL)-BENZOXAZOLE"

• Patent Identification: U.S. Patent No. 9,770,441, "CRYSTALLINE SOLID FORMS OF 6-CARBOXY-2-(3,5-DICHLOROPHENYL)-BENZOXAZOLE," issued September 26, 2017 (the '441 Patent).

The Invention Explained

• Problem Addressed: The patent's background explains that for a pharmaceutical compound, the specific solid form is critical ʻ441 Patent, col. 1:47-50 Different crystalline forms, or polymorphs, of the same active ingredient can possess different physical properties, such as stability and dissolution rates, which can impact a drug's safety and effectiveness ʻ441 Patent, col. 9:40-54 Inconsistency in the solid form during manufacturing or storage can lead to unpredictable product performance ʻ441 Patent, col. 1:50-54
• The Patented Solution: The invention provides specific, identifiable crystalline forms of the compound 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole, the active ingredient in the drug tafamidis ʻ441 Patent, abstract These forms are defined by unique and measurable analytical characteristics, such as specific peaks in a powder X-ray diffraction (PXRD) pattern, distinct chemical shifts in a solid-state nuclear magnetic resonance (NMR) spectrum, or particular peaks in a Raman spectrum ʻ441 Patent, col. 2:7-15 By defining these stable crystalline forms, the invention aims to ensure consistent, reliable production of the drug substance ʻ441 Patent, col. 9:48-54
• Technical Importance: Isolating and characterizing a stable, pure crystalline form of an active pharmaceutical ingredient is a crucial step in drug development, ensuring product consistency, predictable bioavailability, and manufacturability ʻ441 Patent, col. 9:48-54

Key Claims at a Glance

• The complaint asserts claims 1-16, with a focus on independent claim 1 Compl. ¶31
• Independent Claim 1 requires:
  • A crystalline form of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole,
  • wherein the crystalline form possesses an analytical parameter selected from a Markush group consisting of three options:
    • a solid-state NMR spectrum comprising specific ¹³C chemical shifts, OR
    • a powder X-ray diffraction (PXRD) pattern comprising a specific peak, OR
    • a Raman spectrum comprising a specific Raman shift peak.
• The complaint alleges infringement of claims 1-16, thereby reserving the right to assert dependent claims which further narrow the definition of the crystalline form with additional analytical parameters Compl. ¶31 ʻ441 Patent, claims 2-12

III. The Accused Instrumentality

Product Identification

• The accused instrumentality is Cipla's generic tafamidis 61 mg capsules, for which it seeks FDA approval via ANDA No. 218409 ("Cipla's ANDA Product") Compl. ¶2

Functionality and Market Context

• Cipla's ANDA Product is a generic version of Plaintiffs' drug, Vyndamax® Compl. ¶18
• Vyndamax® is approved for treating the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults, a condition related to protein misfolding Compl. ¶16 ʻ441 Patent, col. 1:43-47
• The complaint alleges that Cipla's ANDA Product contains tafamidis, which is the same active ingredient as Vyndamax® and is chemically named 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole Compl. ¶17 Compl. ¶33

IV. Analysis of Infringement Allegations

The complaint does not provide a claim chart or specific technical data from Cipla's ANDA to map the accused product to the patent claims. The infringement theory is based on Cipla's submission of an ANDA for a generic equivalent of Vyndamax®, which Plaintiffs allege is covered by the '441 Patent Compl. ¶27 Compl. ¶31 The core allegation is that Cipla's ANDA Product contains a crystalline form of tafamidis that will meet the analytical parameters of at least one of the asserted claims Compl. ¶31 Compl. ¶33 A detailed infringement analysis will depend on discovery, including the specific characterization data for the crystalline form used in Cipla's ANDA Product.

No probative visual evidence provided in complaint.

• Identified Points of Contention:
  • Factual Question: The central dispute will likely be factual: does the specific crystalline form of tafamidis in Cipla's ANDA Product exhibit the NMR chemical shifts, PXRD peaks, or Raman shift peaks defined in the asserted claims? This question will require expert testing and comparison of the accused product against the claim limitations.
  • Scope Questions: The interpretation of the range limitations in the claims (e.g., a peak at "28.6±0.2") may become a point of contention, raising the question of whether Cipla's product, if its measured peaks are near the boundaries of these ranges, falls within the literal scope of the claims.

V. Key Claim Terms for Construction

• The Term: "crystalline form ... has an analytical parameter selected from the group consisting of..."
• Context and Importance: This Markush group language is central to the infringement analysis. The dispute may turn on whether Cipla's product must be proven to meet only one of the listed analytical parameters (e.g., the PXRD peak) to infringe, or if the overall characteristics of Cipla's crystalline form must be consistent with the form described in the patent. Practitioners may focus on this term because Cipla could argue its product is a novel, non-infringing polymorph that coincidentally shares a single analytical feature but differs in others.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The plain language of the claim requires only that the crystalline form have "an analytical parameter selected from the group." This structure suggests that meeting any one of the listed options is sufficient for infringement.
  • Evidence for a Narrower Interpretation: The patent specification describes specific polymorphs (e.g., "Form 1") characterized by a collection of analytical data ʻ441 Patent, col. 2:16-24 ʻ441 Patent, FIG. 1 ʻ441 Patent, FIG. 5 ʻ441 Patent, FIG. 9 A defendant may argue that the claims, when read in light of the specification, are intended to cover these specific forms in their entirety, and that an accused product must embody the overall character of a disclosed form, not just an isolated analytical feature.

VI. Other Allegations

• Indirect Infringement: The complaint alleges induced infringement, stating that upon approval, Cipla's proposed product labeling will direct and encourage medical professionals and patients to use the product in an infringing manner Compl. ¶34 Compl. ¶39 It also alleges contributory infringement on the basis that Cipla's product is not a staple article of commerce and is especially made or adapted for an infringing use Compl. ¶40
• Willful Infringement: Willfulness is alleged based on Cipla having "full knowledge of the '441 patent" and its intent to manufacture and sell the product prior to the patent's expiration, despite this knowledge Compl. ¶41 Compl. ¶43

VII. Analyst's Conclusion: Key Questions for the Case

• A core issue will be one of evidentiary proof: Can Plaintiffs demonstrate through analytical testing that the specific crystalline solid form of tafamidis used in Cipla's ANDA Product exhibits at least one of the precise spectral or diffraction peaks required by independent claim 1 of the '441 Patent?
• A secondary legal and factual question will be one of polymorphic identity: If Cipla's product meets one of the analytical parameters of claim 1 but can be shown to have other characteristics defining it as a distinct and novel polymorph not disclosed in the patent, can it escape infringement? This will test the scope of Markush claims used to define a specific physical form of a chemical compound.